Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

Menu

PRESS RELEASES

PRESS RELEASES

/

Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity

Virtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's …

[Read more...] about Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity

/

Akari Therapeutics Appoints Former AACR President andRenowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its …

[Read more...] about Akari Therapeutics Appoints Former AACR President andRenowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board